Impax Asset Management Group
KRTX

Impax Asset Management Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Impax Asset Management Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-49,463
Closed -$6.26M – 414
2022
Q2 		$6.26M Sell
49,463
-50,000
-50% -$5.75M 0.03% 180
2022
Q1 		$12.6M Hold
99,463
– – 0.05% 145
2021
Q4 		$13M Buy
99,463
+5,289
+6% +$684K 0.05% 146
2021
Q3 		$11.5M Buy
94,174
+19,711
+26% +$2.28M 0.05% 145
2021
Q2 		$8.49M Buy
74,463
+5,456
+8% +$638K 0.04% 170
2021
Q1 		$8.3M Hold
69,007
– – 0.04% 157
2020
Q4 		$7.01M Buy
69,007
+8,157
+13% +$756K 0.04% 146
2020
Q3 		$4.71M Buy
60,850
+16,700
+38% +$1.42M 0.04% 162
2020
Q2 		$4.92M Buy
+44,150
New +$3.84M 0.05% 154

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Impax Asset Management Group's KRTX Position: Q3 2022 in Review

Impax Asset Management Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2022, closing a stake of 49,463 shares — an estimated $6.26M sold.

Impax Asset Management Group first reported a position in KRTX in Q2 2020 and held it in 9 quarters. The position peaked at $13M in Q4 2021. 257 funds tracked by Wall St. Rank hold KRTX as of Q3 2022.

  • Impax Asset Management Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Impax Asset Management Group sold 49,463 Karuna Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $6.26M.
  • Impax Asset Management Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
  • Impax Asset Management Group's Karuna Therapeutics, Inc. Common Stock position peaked at $13M in Q4 2021.
  • 257 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Impax Asset Management Group's 13F filing for Q3 2022, filed 8 Nov 2022.